Claritev (CTEV) AI Stock Analysis

• Market Cap: $416.45M
• Dividend Yield: N/A
• Average Volume (3M): 192.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.95
• Revenue Growth: 0.89%
• EPS Growth: 78.04%
• Country: US
• Employees: 2,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -4.23
• Shares Outstanding: 16,525,644
• 10 Day Avg. Volume: 112,555
• 30 Day Avg. Volume: 192,199
• PEG Ratio: >-0.01
• Price to Book (P/B): 5.61
• Price to Sales (P/S): 0.51
• P/FCF Ratio: -44.88
• Enterprise Value/Market Cap: 12.05
• Enterprise Value/Revenue: 5.28
• Enterprise Value/Gross Profit: 7.06
• Enterprise Value/Ebitda: 12.12
• 1Y Price Target: $62.00
• Price Target Upside: 31.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $25.00 ▼(-46.94% Downside)

The score is held down primarily by weak financial performance (large losses, negative free cash flow, and a high-risk balance sheet with negative equity) and bearish technicals (price well below key moving averages with negative MACD). These are partially offset by a positive earnings-call outlook (raised guidance, strong renewals, ACV and pipeline growth), while valuation offers limited support due to negative earnings and no dividend yield.

Positive Factors

Recurring revenue and client renewals

High renewal rates of top clients together with $60M new ACV and a 67% larger pipeline materially increase revenue visibility. For a subscription & consulting model this supports predictable recurring cash flows, lowers churn risk, and underpins multi‑period revenue durability.

Improving EBITDA and operating efficiency

Consistent adjusted EBITDA growth and a material positive EBITDA margin indicate improving operating leverage. If management sustains margin expansion through cost discipline and scale, this drives longer‑term cash generation capacity even if GAAP profitability lags.

Strategic expansion and technology investments

Targeted expansion into new verticals and international markets plus investments in data and AI diversify revenue and raise competitive barriers. Over time this broadens addressable market, reduces client concentration risk, and supports higher‑value product offerings and upsell opportunities.

Negative Factors

Negative equity and high leverage

Negative shareholders' equity and reliance on debt financing indicate structural balance sheet weakness. Elevated leverage constrains financial flexibility, raises refinancing risk, and limits the company's ability to absorb shocks or fund inorganic growth without costly external capital.

Negative free cash flow and weak cash conversion

Persistently negative free cash flow and very low cash conversion mean the business still requires external funding to support operations and growth. This limits reinvestment capacity, prolongs dependence on capital markets, and increases vulnerability to higher borrowing costs or funding interruptions.

Healthcare inflation and regulatory headwinds

Structural healthcare reimbursement and regulatory pressures, plus material inflation, can compress payer/provider budgets and slow client spending. For a company serving healthcare data and analytics, this elevates revenue and margin risk and can lengthen sales cycles for multi‑year contracts.

Claritev Business Overview & Revenue Model

Company Description

Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in New York, New York.

How the Company Makes Money

Claritev generates revenue through a subscription-based model for its cloud services, charging clients monthly or annually for access to its platforms. Additionally, the company offers consulting services that help organizations implement data analytics solutions, which contributes to a significant portion of its revenue. Key partnerships with major cloud service providers and healthcare institutions also play a crucial role in driving sales and expanding its customer base, further enhancing its revenue streams.

Claritev Financial Statement Overview

Summary

Overall fundamentals are weak: modest TTM revenue growth (1.65%) is outweighed by heavy losses (net margin -35.93%, EBIT margin -9.07%), negative free cash flow despite improvement, and a highly risky balance sheet with negative stockholders’ equity and elevated leverage.

Income Statement

Claritev's income statement reveals a challenging financial environment. The TTM data shows a slight revenue growth of 1.65%, but the company is struggling with profitability, as evidenced by a negative net profit margin of -35.93% and an EBIT margin of -9.07%. The gross profit margin has decreased significantly from previous years, indicating pressure on cost management. The EBITDA margin remains positive at 26.95%, suggesting some operational efficiency, but overall profitability remains a concern.

Balance Sheet

The balance sheet highlights significant financial leverage, with a negative debt-to-equity ratio due to negative stockholders' equity. This indicates potential financial instability and risk. The return on equity is positive at 31.86%, but this is skewed by the negative equity. The equity ratio is also negative, reflecting the company's reliance on debt financing, which could pose risks if not managed carefully.

Cash Flow

Cash flow analysis shows mixed results. The operating cash flow to net income ratio is low at 0.08, indicating limited cash generation relative to net income. Free cash flow has improved significantly, with a growth rate of 103.34%, but remains negative, highlighting ongoing cash flow challenges. The free cash flow to net income ratio is -6.38, underscoring the need for improved cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	951.00M	930.62M	961.52M	1.08B	1.12B	937.76M
Gross Profit	710.55M	691.22M	726.06M	875.62M	942.31M	619.09M
EBITDA	414.06M	-1.01B	651.93M	158.32M	814.99M	192.41M
Net Income	-341.68M	-1.65B	-91.70M	-572.91M	102.08M	-520.56M
Balance Sheet
Total Assets	4.99B	5.15B	6.96B	7.37B	8.22B	8.28B
Cash, Cash Equivalents and Short-Term Investments	50.65M	16.85M	71.55M	334.05M	185.33M	126.75M
Total Debt	4.65B	4.54B	4.57B	4.78B	4.93B	4.61B
Total Liabilities	5.09B	5.07B	5.26B	5.58B	5.88B	5.73B
Stockholders Equity	-101.83M	84.02M	1.71B	1.79B	2.34B	2.56B
Cash Flow
Free Cash Flow	-113.12M	-10.51M	62.87M	282.63M	320.10M	306.56M
Operating Cash Flow	17.01M	107.62M	171.72M	372.36M	404.69M	377.37M
Investing Cash Flow	-116.79M	-118.12M	-249.79M	-104.45M	-228.38M	-210.84M
Financing Cash Flow	53.26M	-41.31M	-180.99M	-115.74M	-114.68M	-61.60M

Claritev Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 47.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTEV, the sentiment is Negative. The current price of 47.12 is above the 20-day moving average (MA) of 28.99, above the 50-day MA of 36.14, and above the 200-day MA of 44.92, indicating a bearish trend. The MACD of -3.08 indicates Negative momentum. The RSI at 31.80 is Neutral, neither overbought nor oversold. The STOCH value of 19.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTEV.

Claritev Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NUTX	80 Outperform	$884.70M	6.49	63.86%	―	236.03%	―
HSTM	69 Neutral	$605.23M	30.63	5.87%	0.52%	3.68%	5.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HCAT	50 Neutral	$153.49M	-1.37	-31.33%	―	4.64%	-17.17%
DH	49 Neutral	$290.39M	-1.22	-47.69%	―	-5.30%	46.01%
EVH	48 Neutral	$341.50M	-1.95	-13.63%	―	-16.65%	-71.92%
CTEV	44 Neutral	$416.45M	-1.20	-646.34%	―	0.89%	78.04%

Claritev Corporate Events

Claritev outlines long-term growth strategy at healthcare conference

On January 15, 2026, Claritev Corporation made an investor slide presentation available in conjunction with its appearance at the J.P. Morgan 44th Annual Healthcare Conference, outlining its long-term vision to enhance transparency and affordability in healthcare and detailing its multi-year growth strategy from 2024 through 2030. The materials highlight both the scale of Claritev’s operations and the market challenges it aims to address—such as escalating medical inflation, rising employer and employee healthcare costs, regulatory complexity, and systemic waste—positioning the company as a key player seeking to leverage its enterprise data platform and broad payer, employer and provider relationships to drive sustained growth and deeper impact across the healthcare ecosystem.

The most recent analyst rating on (CTEV) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Claritev stock, see the CTEV Stock Forecast page.

Claritev Ends Former CEO’s Strategic Advisory Role

Claritev Corporation disclosed a governance update involving its former Chief Executive Officer and Executive Chair, Dale White, who currently serves on the company’s board of directors. On December 23, 2025, the company announced that White will end his role as a strategic advisor effective December 31, 2025, a position he assumed after stepping down as Executive Chair on December 31, 2024; he will remain a director on the board, the company waived its right to require 30 days’ notice for ending the advisory role, and no additional compensation will be paid for that advisory service, signaling a formal conclusion to his transitional duties while preserving his board-level involvement.

The most recent analyst rating on (CTEV) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Claritev stock, see the CTEV Stock Forecast page.

Claritev Finalizes Underwriting Agreement for Stock Sale

On November 12, 2025, Claritev Corporation entered into an Underwriting Agreement with affiliates of Hellman & Friedman and several underwriters for the sale of 1,500,000 shares of Class A common stock at $51.50 per share. The Offering, which closed on November 14, 2025, did not involve the company selling shares or receiving proceeds, and included a 30-day option for underwriters to purchase an additional 225,000 shares.

The most recent analyst rating on (CTEV) stock is a Hold with a $43.00 price target. To see the full list of analyst forecasts on Claritev stock, see the CTEV Stock Forecast page.